HIVE Fundamental Analysis - HIVE DIGITAL TECHNOLOGIES LT

Fundamental Rating

HIVE gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 63 industry peers in the Software industry. HIVE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HIVE is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year HIVE was profitable.

HIVE had a positive operating cash flow in the past year.

The reported net income has been mixed in the past 5 years: HIVE reported negative net income in multiple years.

HIVE had a positive operating cash flow in each of the past 5 years.

1.2 Ratios

With a decent Return On Assets value of 4.57%, HIVE is doing good in the industry, outperforming 73.02% of the companies in the same industry.

With a decent Return On Equity value of 5.13%, HIVE is doing good in the industry, outperforming 68.25% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	4.57%
ROE	5.13%
ROIC	N/A

ROA(3y)-37.49%

ROA(5y)-16.27%

ROE(3y)-49.77%

ROE(5y)-22%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

HIVE has a better Profit Margin (22.36%) than 93.65% of its industry peers.

The Operating Margin and Gross Margin are not available for HIVE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	22.36%
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

HIVE does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, HIVE has more shares outstanding

HIVE has more shares outstanding than it did 5 years ago.

The debt/assets ratio for HIVE has been reduced compared to a year ago.

2.2 Solvency

An Altman-Z score of 5.43 indicates that HIVE is not in any danger for bankruptcy at the moment.

HIVE has a Altman-Z score of 5.43. This is in the better half of the industry: HIVE outperforms 79.37% of its industry peers.

HIVE has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.

The Debt to Equity ratio of HIVE (0.03) is better than 76.19% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	N/A
Altman-Z	5.43

ROIC/WACCN/A

WACC10.43%

2.3 Liquidity

A Current Ratio of 3.42 indicates that HIVE has no problem at all paying its short term obligations.

HIVE has a better Current ratio (3.42) than 84.13% of its industry peers.

HIVE has a Quick Ratio of 3.42. This indicates that HIVE is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 3.42, HIVE belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.42
Quick Ratio	3.42

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

HIVE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 145.17%, which is quite impressive.

HIVE shows a small growth in Revenue. In the last year, the Revenue has grown by 4.47%.

Measured over the past years, HIVE shows a very strong growth in Revenue. The Revenue has been growing by 31.59% on average per year.

EPS 1Y (TTM)145.17%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%500%

Revenue 1Y (TTM)4.47%

Revenue growth 3Y-18.07%

Revenue growth 5Y31.59%

Sales Q2Q%41.47%

3.2 Future

HIVE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 84.23% yearly.

HIVE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 53.13% yearly.

EPS Next Y1251.77%

EPS Next 2Y368.34%

EPS Next 3Y84.23%

EPS Next 5YN/A

Revenue Next Year167.78%

Revenue Next 2Y102.04%

Revenue Next 3Y53.13%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 22.44, the valuation of HIVE can be described as rather expensive.

Compared to the rest of the industry, the Price/Earnings ratio of HIVE indicates a rather cheap valuation: HIVE is cheaper than 82.54% of the companies listed in the same industry.

HIVE's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.08.

HIVE is valuated cheaply with a Price/Forward Earnings ratio of 7.75.

Based on the Price/Forward Earnings ratio, HIVE is valued cheaper than 92.06% of the companies in the same industry.

The average S&P500 Price/Forward Earnings ratio is at 22.72. HIVE is valued rather cheaply when compared to this.

		Industry Rank	Sector Rank
PE	22.44
Fwd PE	7.75

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

HIVE's earnings are expected to grow with 84.23% in the coming years. This may justify a more expensive valuation.

PEG (NY)0.02

PEG (5Y)N/A

EPS Next 2Y368.34%

EPS Next 3Y84.23%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for HIVE!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

HIVE DIGITAL TECHNOLOGIES LT

TSX-V:HIVE (8/29/2025, 7:00:00 PM)

4.04

0 (0%)

Chartmill FA Rating

GICS SectorInformation Technology

GICS IndustryGroupSoftware & Services

GICS IndustrySoftware

Earnings (Last)08-14 2025-08-14/amc

Earnings (Next)11-13 2025-11-13

Inst Owners17.39%

Inst Owner ChangeN/A

Ins Owners0.28%

Ins Owner ChangeN/A

Market Cap926.53M

Analysts80

Price Target5.87 (45.3%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)185.32%

Min EPS beat(2)100.9%

Max EPS beat(2)269.73%

EPS beat(4)4

Avg EPS beat(4)130.87%

Min EPS beat(4)43.42%

Max EPS beat(4)269.73%

EPS beat(8)7

Avg EPS beat(8)88.66%

EPS beat(12)9

Avg EPS beat(12)16.46%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)0.88%

Min Revenue beat(2)-1.52%

Max Revenue beat(2)3.29%

Revenue beat(4)2

Avg Revenue beat(4)-0.05%

Min Revenue beat(4)-8.08%

Max Revenue beat(4)6.13%

Revenue beat(8)5

Avg Revenue beat(8)3.67%

Revenue beat(12)9

Avg Revenue beat(12)18.5%

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-17.86%

EPS NQ rev (1m)6.06%

EPS NQ rev (3m)-2227.33%

EPS NY rev (1m)712.41%

EPS NY rev (3m)712.41%

Revenue NQ rev (1m)1.63%

Revenue NQ rev (3m)12.12%

Revenue NY rev (1m)1.3%

Revenue NY rev (3m)1.3%

Valuation

		Industry Rank	Sector Rank
PE	22.44
Fwd PE	7.75
P/S	5.24
P/FCF	N/A
P/OCF	22.07
P/B	1.2
P/tB	1.2
EV/EBITDA	N/A

EPS(TTM)0.18

EY4.46%

EPS(NY)0.52

Fwd EY12.9%

FCF(TTM)-0.72

FCFYN/A

OCF(TTM)0.18

OCFY4.53%

SpS0.77

BVpS3.36

TBVpS3.36

PEG (NY)0.02

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	4.57%
ROE	5.13%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	22.36%
GM	N/A
FCFM	N/A

ROA(3y)-37.49%

ROA(5y)-16.27%

ROE(3y)-49.77%

ROE(5y)-22%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0.2

Health

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	206.22%
Cap/Sales	116.51%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.42
Quick Ratio	3.42
Altman-Z	5.43

F-Score5

WACC10.43%

ROIC/WACCN/A

Cap/Depr(3y)97.27%

Cap/Depr(5y)157.57%

Cap/Sales(3y)54.64%

Cap/Sales(5y)58.11%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)145.17%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%500%

EPS Next Y1251.77%

EPS Next 2Y368.34%

EPS Next 3Y84.23%

EPS Next 5YN/A

Revenue 1Y (TTM)4.47%

Revenue growth 3Y-18.07%

Revenue growth 5Y31.59%

Sales Q2Q%41.47%

Revenue Next Year167.78%

Revenue Next 2Y102.04%

Revenue Next 3Y53.13%

Revenue Next 5YN/A

EBIT growth 1Y-98.15%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year280.42%

EBIT Next 3Y69.4%

EBIT Next 5YN/A

FCF growth 1Y-313.96%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-33.66%

OCF growth 3Y-36.92%

OCF growth 5Y84.91%

HIVE DIGITAL TECHNOLOGIES LT (HIVE.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens